Ayahuasca and Public Health : Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users Genís Ona, Maja Kohek, Tomàs Massaguer, Alfred Gomariz, Daniel F. Jiménez, Rafael G. Dos Santos, Jaime E. C. Hallak, Miguel Ángel Alcázar- Córcoles & José Carlos Bouso Journal of Psychoactive Drugs, 2019, DOI: 10.1080/02791072.2019.1567961 ABSTRACT Assessing the health status of ayahuasca users has been challenging due to the limitations involved in randomized clinical trials and psychometric approaches. The main objective of this study is the implementation of an approach based on public health indicators. We developed a self-administered questionnaire that was administered to long-term [...]
Lire la suiteAn Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors Paula Morales and Patricia H. Reggio Cannabis and Cannabinoid Research, 2017, Volume 2.1, 265-273 DOI: 10.1089/can.2017.0036 Abstract The endocannabinoid system (ECS) has been shown to be of great importance in the regulation of numerous physiological and pathological processes. To date, two Class A G-protein-coupled receptors (GPCRs) have been discovered and validated as the main therapeutic targets of this system: the cannabinoid receptor type 1 (CB1), which is the most abundant neuromodulatory receptor in the brain, and the cannabinoid receptor type 2 (CB2), predominantly found in the immune system among other organs and tissues. Endogenous cannabinoid receptor [...]
Lire la suiteIbogaine : A review - Chapter 1 Kenneth R. Alper The Alkaloids. Chemistry and Biology, 2001, 56, 38 pp DOI: 10.1016/S0099-9598(01)56005-8 I. Introduction, Chemical Properties, and Historical Time Line ..................... A. Introduction................................................................................................... B. Chemical Structure and Properties .............................................................. C. Historical Time Line ..................................................................................... II. Mechanisms of Action .................................................................................. A. Neurotransmitter Activities........................................................................... B. Discrimination Studies.................................................................................. C. Effects on Neuropeptides............................................................................... D. Possible Effects on Neuroadaptations Related to Drug Sensitization or Tolerance ....................................................................................................... III. Evidence of Efficacy in Animal Models........................................................ A. Drug Self-Administration .............................................................................. B. Acute Opioid Withdrawal .............................................................................. C. Conditioned Place Preference........................................................................ D. Locomotor Activity........................................................................................ E. Dopamine Efflux............................................................................................. IV Evidence of Efficacy and Subjective Effects in Humans .............................. A. Evidence of Efficacy........................................................................................ B. Subjective Effects ........................................................................................... V. Pharmacokinetics ........................................................................................... A. Absorption....................................................................................................... B. Distribution .................................................................................................... C. Metabolism .................................................................................................... D. Excretion [...]
Lire la suiteThe fourfold discovery of Mescaline (1896–1919) Ivo Gurschler Chemical Monthly, 2019, 150, 941–947 © Springer-Verlag GmbH Austria, part of Springer Nature 2019 https://doi.org/10.1007/s00706-019-02444-0 Abstract This is an historical account of the pharmacological, chemical, and anthropological research concerning the molecular makeup of the peyote cactus (Lophophora williamsii) that laid the ground for Ernst Spaeth’s structural elucidation of mescaline as 3,4,5-trimethoxyphenethylamine. Keywords : History of science · Psychedelic studies · Organic chemistry · Alkaloids · Mescaline · Drugs Introduction The exploration of the constituents of the peyote cactus and its effects upon the human psyche was an interdisciplinary undertaking that defied national borders. The material way to the heart of the [...]
Lire la suiteAyahuasca Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Genís Oña -2013- Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org Content _____________________________________ 1. What is ayahuasca? 2. Scientific papers about ayahuasca arranged chronologically (1969-2013) - G. R. Dolmatoff (1969). El contexto cultural de un alucinógeno aborigen : Banisteriopsis Caapi - C. Grob et al. (1996). Human Psychopharmacology of Hoasca, a Plant Hallucinogen Used in Ritual Context in Brazil - J. C. Callaway et al. (1999). Pharmacokinetics of Hoasca Alkaloids in Healthy Humans - B. Shanon (2000). Ayahuasca and [...]
Lire la suitePsilocybin Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Fco. Miguel Ríos & Genís Oña - 2014 - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org Content _____________________________________ 1. What is Psilocybin? 2. Scientific papers about Psilocybin arranged chronologically (1959-2014) - A. Hofmann (1959). Chemical Aspects of Psilocybin, the Psychotropic Principle from the Mexican Fungus, Psilocybe Mexicana Heim - S. Malitz et al. (1960). Some Observations on Psilocybin, a New Hallucinogen, in Volunteer Subjects - L. E. [...]
Lire la suiteThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]
Lire la suitePsychedelic Induced Transpersonal Experiences, Therapies, and Their Implications for Transpersonal Psychology Thomas B. Roberts and Michael J. Winkelman Chapter 25 - The Wiley-Blackwell Handbook of Transpersonal Psychology, First Edition. Edited by Harris L. Friedman and Glenn Hartelius. © 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd. Psychedelics and other natural and synthetic substances have an ability to induce a range of transpersonal experiences. The predominance of spiritually-related experiences from these substances has led to the development of the concept of entheogen— reflecting their potential to produce an internal experience of communing with god. The similarity of the drug-induced transpersonal [...]
Lire la suiteThe Pharmacology of Lysergic Acid Diethylamide : a Review Torsten PASSIE, John H. HALPERN, Dirk O. STICHTENOTH, Hinderk M. EMRICH, Annelie HINTZEN CNS Neuroscience & Therapeutics, 2008, 14, 295-314. Doi: 10.1111/j.1755-5949.2008.00059.x Lysergic acid diethylamide (LSD) was synthesized in 1938 and its psychoactive effects discovered in 1943. It was used during the 1950s and 1960s as an experimental drug in psychiatric research for producing so-called “experimental psychosis” by altering neurotransmitter system and in psychotherapeutic procedures (“psycholytic” and “psychedelic” therapy). From the mid 1960s, it became an illegal drug of abuse with widespread use that continues today. With the entry of new methods of research and [...]
Lire la suiteDose-related Effects of Salvinorin A in Humans : Dissociative, Hallucinogenic, and Memory Effects MacLEAN K.A., JOHNSON M.W., REISSIG C.J., PRISINZANO T.E., GRIFFITHS R.R. : Psychopharmacology (Berl), 2013, 226, (2), 381–392. doi: 10.1007/s00213-012-2912-9 Abstract Rationale—Salvinorin A is a kappa opioid agonist and the principal psychoactive constituent of the plant Salvia divinorum, which has increased in popularity as a recreational drug over the past decade. Few human studies have examined salvinorin A. Objective—This double-blind, placebo-controlled study evaluated the dose-related effects of inhaled salvinorin A in individuals with histories of hallucinogen use. Methods—Eight healthy hallucinogen-using adults inhaled up to 16 doses of salvinorin A (0.375 - 21 μg/kg) in ascending order. Physiological, behavioral, [...]
Lire la suite